Oral Insulin | Page 3 of 3

Oral Insulin AFREZZA Successful at Controlling Blood Sugar Levels in Type 1 Diabetes Patients

MannKind announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin (also combined with basal insulin), in reducing HbA1c levels in subjects with inadequately controlled type 1 diabetes...

Study Shows AFREZZA Safe and Effective in Controlling Blood Glucose Levels

MannKind Corp. announced the results of a two year study comparing the efficacy and safety of AFREZZA (insulin human [rDNA origin]) versus usual diabetes care. The study followed patients for a total of up to two years. The patients were randomly assigned to a treatment regimen of either AFREZZA plus...

FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA

MannKind Corporation announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA(TM) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes...

Novo Nordisk Starts Phase 1 Trial With Oral Insulin

Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). The aim of the trial, conducted in Germany, is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin in healthy volunteers and people with type 1 and type 2 diabetes...

Novo Nordisk: Progress Made in Oral Insulin Development

Lars Sorensen, Novo's chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral insulin tablet to the market within six years. A number of companies have already tried to develop inhaled insulin, including Pfizer Inc, whose product Exubera, was discontinued in 2007. This form of insulin has raised concerns that it could cause lung damage.